GreenRoc Accelerates their World Class Project to Production as Early as 2028. Watch the full video here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksGlaxosmithkline Share News (GSK)

Share Price Information for Glaxosmithkline (GSK)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 1,650.50
Bid: 1,652.00
Ask: 1,652.50
Change: 35.50 (2.20%)
Spread: 0.50 (0.03%)
Open: 1,631.00
High: 1,663.50
Low: 1,630.50
Prev. Close: 1,615.00
GSK Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

LONDON MARKET PRE-OPEN: Glaxo gets US approval; Senior trades in line

Fri, 23rd Apr 2021 07:53

(Alliance News) - Stock prices in London are seen opening lower on Friday, tracking declines in US equity markets overnight after reports the Biden administration is planning additional tax hikes, while investor focus in Europe will be on a slew of PMI readings.

In early company news, drugmaker GlaxoSmithKline's dostarlimab treatment was approved in the US. Aerospace parts maker Senior said first-quarter trading was in line with expectations.

IG futures indicate the FTSE 100 index is to open 24.64 points lower at 6,913.60. The blue-chip index closed up 42.95 points, or 0.6%, at 6,938.24 Thursday.

Senior said trading in the three months to March 31 has been in line with expectations. In the Aerospace unit, sales were down 25% for the the first quarter last year, but up 2% from the fourth quarter. In the Flexonic unit, sales were down 4% from the first quarter last year but up 10% from the fourth quarter.

Senior said net debt at end of March GBP220.8 million, giving GBP140.6 million headroom on its facilities.

Senior said its 2021 market assumptions remain unchanged, and defence markets are anticipated to remain stable. However, civil aircraft production volumes look set to recover to pre-Covid level only by 2024-25, it said.

"Production volumes for civil aerospace will be lower in 2021 than 2020 based on the production rates that the aircraft and engine OEMs have announced. We also recognise that there are varying levels of inventory in different tiers of the supply chain," the company said.

GlaxoSmithKline said the US Food & Drug Administration has approved the drugmaker's Jemperli treatment for women with recurrent or advanced endometrial cancer.

The approval was for patients with cancer who had progressed on or after previous treatment with platinum-based chemotherapy and whose cancers have a deficient mismatch repair genetic anomaly.

"Unfortunately, as many as 60,000 women are diagnosed with endometrial cancer in the US each year and these women currently have limited treatment options if their disease progresses on or after first-line therapy. Today's approval of dostarlimab by the FDA has the potential to transform the treatment landscape for these women and demonstrates our continued commitment to helping patients with gynaecologic cancers," said Chief Scientific Officer Hal Barron.

In the US on Thursday, Wall Street ended lower, with the Dow Jones Industrial Average, S&P 500 and Nasdaq Composite indices all down 0.9%.

US President Joe Biden is planning to almost double the capital gains tax rate for wealthy individuals to 39.6%, Bloomberg News reported Thursday evening.

This would be an increase from the current rate of 20%, and would apply to those earning USD1 million or more. For those high earners the new top rate, coupled with an existing surtax on investment income, means that federal tax rates could be as high as 43.4%.

A 3.8% tax on investment income that funds Obamacare would be kept in place, pushing the tax rate on returns on financial assets higher than rates on some wage and salary income, Bloomberg noted.

The proposal could reverse a long-standing provision of the tax code that taxes returns on investment lower than on labour. Biden campaigned on equalising the capital gains and income tax rates for wealthy individuals.

"Last night's reports are likely to be the opening salvo of a guerrilla war campaign between Democrats and Republicans on how to pay for the huge fiscal stimulus plan that has only just been unleashed as recently as a month ago. For the Democrats to then go ahead and torpedo the effects of that with a raft of tax hikes would be moronic in the extreme. This story is likely to run for quite a while yet," said CMC Markets analyst Michael Hewson.

"Even so European markets look set to open below where they closed last night as a result of last night's sell off," Hewson added.

The Japanese Nikkei 225 index closed down 0.6% on Friday. In China, the Shanghai Composite was down 0.1%, while the Hang Seng index in Hong Kong was up 0.7%. The S&P/ASX 200 in Sydney closed 0.1% lower.

Japan saw renewed expansion in private sector output in April with manufacturing leading the way, figures from au Jibun Bank showed.

The headline au Jibun Bank manufacturing purchasing managers' index rose to 53.3 points in April from 52.7 in March. Both output and new orders expanded at a solid pace, with growth for both the quickest since since the first half of 2018.

The flash manufacturing output index in April rose to 54.2 points, up from 53.3 in March. The flash services business activity index was flat, however, at 48.3 points, signalling a sustained deterioration in business activity in across the service sector.

Overall, the flash composite output index edged up to 50.2 points, up from 49.9 in April, and peaking its head just about the 50-mark neutral line, where anything above 50 denotes. This means Japan's private sector expanded for the first time since January 2020.

The pound was quoted at USD1.3857 early Friday, up from USD1.3838 at the London equities close Thursday.

The euro was priced at USD1.2027, up from USD1.2014. Against the yen, the dollar was quoted at JPY107.88, down from JPY108.11.

Brent oil was trading at USD65.80 a barrel Friday morning, up from USD65.58 at the London equities close Thursday. Gold was quoted at USD1,783.11 an ounce, little changed against USD1,782.29.

The economic calendar on Friday has a raft of purchasing managers' index readings, with Germany at 0830 BST, the eurozone at 0900 BST, the UK at 0930 BST and the US at 1445 BST.

By Arvind Bhunjun; arvindbhunjun@alliancenews.com

Copyright 2021 Alliance News Limited. All Rights Reserved.

More News
1 Nov 2023 07:27

GSK hikes guidance after strong third quarter

(Sharecast News) - GSK announced a robust third quarter on Wednesday, prompting an upgrade to its full-year guidance.

Read more
30 Oct 2023 09:01

IN BRIEF: GSK says Jemperli meets endpoint in endometrial cancer trial

GSK PLC - Brentford, west London-based pharmaceutical maker - Jemperli, whose generic name is dostarlimab, meets endpoint of overall survival in phase III Ruby trial on adult patients with primary advanced or recurrent endometrial cancer. Jemperli, combined with standard-of-care chemotherapy, followed by dostarlimab, demonstrated a "statistically significant and clinically meaningful benefit" to the patients in the trial.

Read more
30 Oct 2023 07:06

GSK's Jemperli sees success in endometrial cancer trial

(Sharecast News) - GSK reported encouraging outcomes from part one of the 'RUBY' phase three trial evaluating the efficacy of 'Jemperli', or dostarlimab, with standard chemotherapy for treating adult patients with advanced or recurrent endometrial cancer on Monday.

Read more
26 Oct 2023 09:19

TOP NEWS: GSK subsidiary ViiV receives HIV drug approval in China

(Alliance News) - GSK PLC on Thursday said its subsidiary ViiV Healthcare has received marketing authorisation in China for its cabotegravir treatment, marketed as Vocabria.

Read more
26 Oct 2023 07:02

GSK HIV injection regimen gets approval in China

(Sharecast News) - GSK announced on Thursday that its majority-owned HIV specialist subsidiary ViiV has received approval from the National Medical Products Administration (NMPA) of China for an injection regimen.

Read more
25 Oct 2023 16:01

UK earnings, trading statements calendar - next 7 days

Thursday 26 October 
Bank of Ireland Group PLCTrading Statement
Bloomsbury Publishing PLCHalf Year Results
Botswana Diamonds PLCTrading Statement
C&C Group PLCHalf Year Results
e-Therapeutics PLCHalf Year Results
Financials Acquisition CorpTrading Statement
GCP Infrastructure Investments LtdTrading Statement
HarbourVest Global Private Equity LtdHalf Year Results
Hummingbird Resources PLCTrading Statement
Hunting PLCTrading Statement
Inchcape PLCTrading Statement
International Personal Finance PLCTrading Statement
PPHE Hotel Group LtdTrading Statement
Renishaw PLCTrading Statement
Standard Chartered PLCQ3 Results
Unilever PLCTrading Statement
WPP PLCTrading Statement
Friday 27 October 
International Consolidated Airlines Group SAQ3 Results
NatWest Group PLCQ3 Results
Monday 30 October 
Airtel Africa PLCHalf Year Results
Computacenter PLCTrading Statement
Glencore PLCTrading Statement
HSBC Holdings PLCQ3 Results
Lok'n Store Group PLCFull Year Results
Pearson PLCTrading Statement
Tuesday 31 October 
BP PLCQ3 Results
Coca-Cola HBC AGTrading Statement
Elementis PLCTrading Statement
essensys PLCFull Year Results
Georgia Capital PLCQ3 Results
Grit Real Estate Income Group LtdFull Year Results
RHI Magnesita NVTrading Statement
Spectris PLCQ3 Results
TP ICAP Group PLCTrading Statement
UP Global Sourcing Holdings PLCFull Year Results
Wednesday 1 November 
Asos PLCFull Year Results
Aston Martin Lagonda Global Holdings PLCQ3 Results
Beximco Pharmaceuticals LtdFull Year Results
GSK PLCQ3 Results
Next PLCTrading Statement
Smurfit Kappa Group PLCTrading Statement
Weir Group PLCTrading Statement
  
Copyright 2023 Alliance News Ltd. All Rights Reserved.

Read more
25 Oct 2023 09:35

GSK says RSV jab shows promising response in adults aged 50 to 59

(Alliance News) - GSK PLC on Wednesday said a trial found its respiratory syncytial virus vaccine Arexy delivered an immune response in adults aged 50 to 59.

Read more
25 Oct 2023 07:27

GSK hails success in US RSV vaccine trial

(Sharecast News) - Pharma giant GSK has announced positive preliminary results from a trial of its Arexvy vaccine to treatment respiratory syncytial virus (RSV) disease for a younger patient population in the US.

Read more
16 Oct 2023 08:09

TOP NEWS: GSK receives positive EU opinion on Jemperli for cancer

(Alliance News) - GSK PLC on Monday said its monoclonal antibody Jemperli is closer to becoming the first new frontline treatment option in the EU in decades for a certain form of endometrial cancer.

Read more
16 Oct 2023 07:44

LONDON BRIEFING: Hipgnosis pulls interim dividend on lower royalties

(Alliance News) - The FTSE 100 is likely to open higher on Monday, benefitting from higher oil and gas prices, while fears of escalating regional conflict in the Middle East damp risk sentiment elsewhere.

Read more
16 Oct 2023 07:16

GSK nears green light for Jemperli usage in Europe

(Sharecast News) - Pharma giant GSK has announced that European experts recommended the approval of its Jerperli drug for the treatment of a specific type of endometrial cancer - paving the way for marketing authorisation by the continent's regulatory body.

Read more
11 Oct 2023 11:51

GSK settles California Zantac lawsuit

(Sharecast News) - GSK has agreed to settle another lawsuit concerning its discontinued heartburn treatment Zantac, the drugs giant confirmed on Wednesday.

Read more
11 Oct 2023 09:17

LONDON BROKER RATINGS: JPMorgan raises Croda; Berenberg cuts Atalaya

(Alliance News) - The following London-listed shares received analyst recommendations Wednesday morning:

Read more
11 Oct 2023 08:51

LONDON MARKET OPEN: FTSE 100 higher; Travis Perkins warns on profit

(Alliance News) - Stock prices in London opened largely higher on Wednesday as market mood remained resilient, despite the continuing conflict in the Middle East, amid a softening of rhetoric from the US central bank.

Read more
11 Oct 2023 08:36

TOP NEWS: GSK reaches settlement for Zantac litigation in California

(Alliance News) - GSK PLC on Wednesday said that it has reached a confidential settlement in the Cantlay/Harper case, which alleged that the firm's heartburn medication can cause cancer.

Read more

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.